SPRi Technology

Surface Plasmon Resonance imaging — label-free, multiplex detection for bio-interaction analysis.

GenOptics pioneered SPRi instrumentation for high-throughput screening of peptides, antibodies, and proteins, enabling researchers to monitor biomolecular interactions in real time without fluorescent or enzymatic labels.

How SPRi Works


Surface Plasmon Resonance imaging combines the sensitivity of classical SPR with array-based spatial resolution. A polarized light source excites surface plasmons on a gold-coated sensor chip; changes in refractive index at the surface — caused by biomolecular binding — are detected in real time across hundreds of spots simultaneously.

Because detection is label-free, SPRi avoids the conformational changes and steric hindrance that fluorescent tags can introduce, yielding kinetic data (association and dissociation rates) that more closely reflects native binding behaviour.

Surface Plasmon Resonance imaging represents a significant advancement in the study of biomolecular interactions, offering researchers the ability to monitor binding events in real time without the need for labels. This technology utilizes a gold-coated sensor chip where changes in refractive index are detected as molecules interact at the surface. The SPRi approach combines the sensitivity of traditional SPR with spatial resolution across an array, enabling simultaneous analysis of multiple targets. This makes it particularly valuable for applications in drug discovery, antibody characterization, and protein interaction studies where high-throughput data is essential for understanding complex biological systems.

The instrumentation developed for SPRi allows scientists to conduct multiplex detection across dozens or even hundreds of spots on a single sensor chip. This parallel processing capability dramatically increases experimental efficiency while maintaining the label-free detection that preserves native molecular behavior. Researchers can observe association and dissociation kinetics in real time, gaining insights into binding affinity and specificity that are critical for therapeutic development. The technology has found particular utility in screening peptide libraries, characterizing monoclonal antibodies, and studying protein-protein interactions within the growing field of proteomics and systems biology.

Modern SPRi systems are designed with user-friendly interfaces that streamline experimental workflow from chip preparation through data analysis. The optical configuration typically employs a polarized light source and a sensitive detector array to capture high-resolution images of the sensor surface. Temperature control and fluidic systems ensure stable conditions for reproducible measurements across runs. As the demand for rapid, information-rich biomolecular analysis continues to grow across pharmaceutical and academic research settings, SPRi technology stands as a powerful tool for generating meaningful kinetic data without the complexity associated with alternative labeling approaches.

A laboratory optical bench with a compact SPRi instrument, gold sensor chip, and precision optics illuminated by warm amber indicator lights against a clean white benchtop.

Core Capabilities


L

Label-Free Detection

Monitor binding events directly — no dyes, tags, or secondary reporters required. Eliminates label-induced artifacts and simplifies assay workflows.

M

Multiplex Analysis

Array-format imaging captures hundreds of interactions in a single experiment, dramatically increasing throughput for screening campaigns.

R

Real-Time Kinetics

Continuous monitoring delivers association and dissociation rate constants, affinity values, and concentration data from one injection.

Applications


SPRi technology serves a broad range of bio-affinity investigation needs:

  • Peptide screening — map epitopes and identify binding motifs across large peptide libraries.
  • Antibody characterization — rank candidates by affinity and specificity early in development.
  • Protein–protein interaction studies — quantify binding kinetics without modifying either partner.
  • Small-molecule fragment screening — detect low-molecular-weight hits in label-free format.
  • Nucleic acid hybridization — monitor DNA/RNA probe binding for biosensor and diagnostic research.

Integration with HORIBA Scientific


Following the acquisition of GenOptics by HORIBA Jobin Yvon in April 2009, SPRi technology joined the HORIBA Scientific portfolio. The merger, completed in 2010, placed GenOptics' label-free detection platform alongside HORIBA's broader spectroscopy and surface-analysis instrumentation, extending support and application reach for SPRi users worldwide.

Questions about SPRi?
Contact our technical team at contact@genoptics-spr.com